valsartan has been researched along with Coronary Restenosis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YH; Lai, HC; Lee, WL; Liu, TJ | 1 |
| Koehler, B; Peters, S; Rählert-Sommer, A; Selbig, D; Steffen, H; Trümmel, M | 1 |
| Dohi, Y; Fujii, T; Hayashi, Y; Ishibashi, K; Kihara, Y; Kurisu, S; Okada, T; Okimoto, T; Otsuka, M; Tadehara, F; Yamamoto, H | 1 |
| Sato, H | 1 |
| Wilensky, RL | 1 |
| Koehler, B; Meyners, W; Peters, S; Trümmel, M; Westermann, K | 1 |
| Chen, H; Ding, RJ; Jia, SQ; Li, GH; Li, HW; Wang, L; Yao, DK; Zhao, L | 2 |
| Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B | 1 |
| Peters, S | 1 |
2 review(s) available for valsartan and Coronary Restenosis
| Article | Year |
|---|---|
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Coronary Restenosis; Female; Humans; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin-receptor blockers: revival of the systemic prevention of restenosis?
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Coronary Restenosis; Humans; Receptors, Angiotensin; Stents; Tetrazoles; Valine; Valsartan | 2003 |
3 trial(s) available for valsartan and Coronary Restenosis
| Article | Year |
|---|---|
Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Endpoint Determination; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Prospective Studies; Stents; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Intercellular Adhesion Molecule-1; L-Selectin; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2007 |
Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Sex Factors; Stents; Tetrazoles; Valine; Valsartan | 2008 |
6 other study(ies) available for valsartan and Coronary Restenosis
| Article | Year |
|---|---|
Iatrogenic Takotsubo Cardiomyopathy Following Overdose Norepinephrine Administration During Percutaneous Coronary Intervention.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Bisoprolol; Coronary Restenosis; Creatine Kinase; Creatine Kinase, MB Form; Drug Overdose; Drug-Eluting Stents; Echocardiography; Humans; Hypotension; Iatrogenic Disease; Intra-Aortic Balloon Pumping; Intraoperative Complications; Male; Medication Errors; Middle Aged; Norepinephrine; Percutaneous Coronary Intervention; Recovery of Function; Shock, Cardiogenic; Stents; Stroke Volume; Takotsubo Cardiomyopathy; Troponin I; Valsartan; Vasoconstrictor Agents | 2020 |
Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions.
Topics: Administration, Oral; Aged; Cohort Studies; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Metals; Middle Aged; Postoperative Complications; Stents; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
[Coronary stenting. Does AT-1 blocker protect from restenosis?].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Restenosis; Humans; Placebos; Stents; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Restenosis; Coronary Stenosis; Female; Humans; Male; Middle Aged; Stents; Tetrazoles; Valine; Valsartan | 2005 |
Effect of valsartan-eluting stents on the expression of angiotensin II type 2 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug Delivery Systems; Immunohistochemistry; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reverse Transcriptase Polymerase Chain Reaction; Stents; Tetrazoles; Valine; Valsartan | 2006 |
[Valsartan eluting-stents inhibited neointimal hyperplasia by decreasing collagen deposition in rabbits].
Topics: Animals; Collagen; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hyperplasia; Male; Rabbits; Tetrazoles; Tunica Intima; Valine; Valsartan | 2006 |